Develops next-generation biologic medicines for colon-associated and other autoimmune diseases, addressing unmet needs in Crohn’s disease patients. Lead program: a first-in-class dual-targeting bispecific nanobody that blocks immune cell migration and eliminates pathogenic cells to enable durable remission; pipeline includes precision biologics and novel therapeutic modalities.